E2 proteins of high risk human papillomaviruses down-modulate STING and IFN-κ transcription in keratinocytes

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Sunthamala, Nuchsupha ^a,b   Thierry, Francoise ^b   Teissier, Sebastien ^b   Pientong, Chamsai ^a   Kongyingyoes, Bunkerd ^a   Tangsiriwatthana, Thumwadee ^c   Sangkomkamhang, Ussanee ^c   Ekalaksananan, Tipaya ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^c KHON KAEN HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; INTERFERON; INTERFERON STIMULATED GENE PROTEIN; KAPPA INTERFERON; STIMULATOR OF INTERFERON GENE PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VIRUS E2 PROTEIN; VIRUS PROTEIN; DNA BINDING PROTEIN; E2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; INTERFERON KAPPA; MEMBRANE PROTEIN; MESSENGER RNA; MPYS PROTEIN, HUMAN; ONCOGENE PROTEIN E2, HUMAN PAPILLOMAVIRUS TYPE 18; ONCOPROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER GRADING; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNE EVASION; INNATE IMMUNITY; KERATINOCYTE; MICROARRAY ANALYSIS; PERSISTENT VIRUS INFECTION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TRANSACTIVATION; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; WART VIRUS; ADENOVIRIDAE; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; GENE REGULATORY NETWORK; GENETIC RECOMBINATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN GENOME; METABOLISM; PROTEIN TERTIARY STRUCTURE;

ADENOVIRIDAE; CELLS, CULTURED; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE REGULATORY NETWORKS; GENOME, HUMAN; GREEN FLUORESCENT PROTEINS; HUMANS; INTERFERON TYPE I; KERATINOCYTES; MEMBRANE PROTEINS; ONCOGENE PROTEINS, VIRAL; POLY I-C; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RECOMBINATION, GENETIC; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC;

EID: 84897518806     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091473     Document Type: Article

References (54)

1. Koutsky L (1997) Epidemiology of genital human papillomavirus infection. Am J Med 102: 3-8. (Pubitemid 127695953)
2. Peto J, Gilham C, Deacon J, Taylor C, Evans C, et al. (2004) Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 91: 942-953. (Pubitemid 39273789)
3. Zur Hausen H (1996) Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1288: F55-78. (Pubitemid 26335492)
4. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244-265. (Pubitemid 34293391)
5. Zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350. (Pubitemid 37328947)
6. Woo YL, van den Hende M, Sterling JC, Coleman N, Crawford RA, et al. (2010) A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6-and E7-specific T-cell responses. Int J Cancer 126: 133-141.
7. Davidson EJ, Sehr P, Faulkner RL, Parish JL, Gaston K, et al. (2003) Human papillomavirus type 16 E2-and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia. J Gen Virol 84: 2089-2097. (Pubitemid 36927238)
8. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, et al. (2011) Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 103: 368-383.
9. Palm NW, Medzhitov R (2009) Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227: 221-233.
10. Takeuchi O, Akira S (2009) Innate immunity to virus infection. Immunol Rev 227: 75-86.
11. Beutler BA (2009) TLRs and innate immunity. Blood 113: 1399-1407.
12. Kaisho T, Akira S (2006) Toll-like receptor function and signaling. J Allergy Clin Immunol 117: 979-987.
13. Bowie AG, Unterholzner L (2008) Viral evasion and subversion of pattern-recognition receptor signaling. Nat Rev Immunol 8: 911-922.
14. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA (2011) Pattern recognition receptors and the innate immune response to viral infection. Viruses 3: 920-940.
15. Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS (2005) E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J cancer 113: 276-283. (Pubitemid 39628318)
16. Bauer M, Wagner H, Lipford GB (2000) HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented. Immunol lett 71: 55-59. (Pubitemid 30068612)
17. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, et al. (2001) Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 167: 5420-5428. (Pubitemid 33009783)
18. Arany I, Goel A, Tyring SK (1995) Interferon response depends on viral transcription in human papillomavirus-containing lesions. Anticancer Res 15: 2865-2869. (Pubitemid 26095114)
19. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, et al. (2000) Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 275: 6764-6769.
20. Um SJ, Rhyu JW, Kim EJ, Jeon KC, Hwang ES, et al. (2002) Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer letters 179: 205-212.
21. Au WC, Moore PA, Lowther W, Juang YT, Pitha PM (1995) Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci USA 92: 11657-11661. (Pubitemid 26014172)
22. Li S, Labrecque S, Gauzzi MC, Cuddihy AR, Wong AH, et al. (1999) The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 18: 5727-5737. (Pubitemid 29507426)
23. Hegde RS, Androphy EJ (1998) Crystal structure of the E2 DNA-binding domain from human papillomavirus type 16: implications for its DNA binding-site selection mechanism. J Mol Biol 284: 1479-1489. (Pubitemid 28566082)
24. Blakaj DM, Fernandez-Fuentes N, Chen Z, Hegde R, Fiser A, et al. (2009) Evolutionary and biophysical relationships among the papillomavirus E2 proteins. Front Biosci 14: 900-917.
25. Kadaja M, Silla T, Ustav E, Ustav M (2009) Papillomavirus DNA replication-from initiation to genomic instability. Virology 384: 360-368.
26. Oliveira JG, Colf LA, McBride AA (2006) Variations in the association of papillomavirus E2 proteins with mitotic chromosomes. Proc Natl Acad Sci USA 103: 1047-1052. (Pubitemid 43212219)
27. Oldak M, Maksym RB, Sperling T, Yaniv M, Smola H, et al. (2010) Human papillomavirus type 8 E2 protein unravels JunB/Fra-1 as an activator of the beta4-integrin gene in human keratinocytes. J Virol. 84: 1376-1386.
28. Mole S, McFarlane M, Chuen-Im T, Milligan SG, Millan D, et al. (2009) RNA splicing factors regulated by HPV16 during cervical tumour progression. J Pathol 219: 383-391.
29. Bellanger S, Tan CL, Xue YZ, Teissier S, Thierry F (2011) Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression. Am J Cancer Res 1: 373-389.
30. Demeret C, Garcia-Carranca A, Thierry F (2003) Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein. Oncogene 22: 168-175. (Pubitemid 36174174)
31. Blachon S, Bellanger S, Demeret C, Thierry F (2005) Nucleo-cytoplasmic shuttling of high risk human papillomavirus E2 proteins induces apoptosis. J Biol Chem 280: 36088-36098. (Pubitemid 41633880)
32. Xue Y, Lim D, Zhi L, He P, Abastado JP, et al. (2012) Loss of HPV16 E2 protein expression without disruption of the E2 ORF correlates with carcinogenic progression. Open Virol J 6: 163-172.
33. Dowhanick JJ, McBride AA, Howley PM (1995) Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 69: 7791-7799.
34. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F (1997) Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 16: 504-514. (Pubitemid 27067780)
35. Stubenrauch F, Hummel M, Iftner T, Laimins LA (2000) The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratino-cytes. J Virol 74: 1178-1186. (Pubitemid 30044067)
36. Stubenrauch F, Straub E, Fertey J, Iftner T (2007) The E8 repression domain can replace the E2 transactivation domain for growth inhibition of HeLa cells by papillomavirus E2 proteins. Int J Cancer 121: 2284-2292. (Pubitemid 47585611)
37. Ishikawa H, Barber GN (2008) STING is an endoplasmic reticulum adaptor that facilitates innate immune signaling. Nature 455: 674-678.
38. Ramirez-Salazar E, Centeno F, Nieto K, Valencia-Hernandez A, Salcedo M, et al. (2011) HPV16 E2 could act as down-regulator in cellular genes implicated in apoptosis, proliferation and cell differentiation. Virol J 8: 247.
39. Zhong B, Yang Y, Li S, Wang YY, Li Y, et al. (2008) The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 29: 538-550.
40. Tanaka Y, Chen ZJ (2012) STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal 5: ra20.
41. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, et al. (2001) Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem 276: 39765-39771.
42. DeCarlo CA, Severini A, Edler L, Escott NG, Lambert PF, et al. (2010) IFN-kappa, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytes. Lab Invest 90: 1482-1491.
43. Rincon-Orozco B, Halec G, Rosenberger S, Muschik D, Nindl I, et al. (2009) Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res 69: 8718-8725.
44. Reiser J, Hurst J, Voges M, Krauss P, Munch P, et al. (2011) High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol 85: 11372-11380.
45. Schindler C, Darnell JE Jr (1995) Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 64: 621-651.
46. De Maeyer E, De Maeyer-Guignard J (1998) Type I interferons. Int Rev Immunol 17: 53-73. (Pubitemid 29014545)
47. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67: 227-264. (Pubitemid 28411130)
48. McBride AA (2013) The papillomavirus E2 proteins. Virology 445: 57-79.
49. Yasugi T, Vidal M, Sakai H, Howley PM, Benson JD (1997) Two classes of human papillomavirus type 16 E1 mutants suggest pleiotropic conformational constraints affecting E1 multimerization, E2 interaction, and interaction with cellular proteins. J Virol 71: 5942-5951. (Pubitemid 27304931)
50. Abbate EA, Berger JM, Botchan MR (2004) The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2. Genes Dev 18: 1981-1996. (Pubitemid 39071580)
51. You J, Croyle JL, Nishimura A, Ozato K, Howley PM (2004) Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 117: 349-360. (Pubitemid 38534541)
52. Bellanger S, Demeret C, Goyat S, Thierry F (2001) Stability of the human papillomavirus type 18 E2 protein is regulated by a proteasome degradation pathway through its amino-terminal transactivation domain. J Virol 75: 7244-7251. (Pubitemid 32737984)
53. Muller M, Jacob Y, Jones L, Weiss A, Brino L, et al. (2012) Large scale genotype comparison of human papillomavirus E2-host interaction networks provides new insights for E2 molecular functions. PLoS Pathog 8: e1002761.
54. Muller M, Demeret C (2012) The HPV E2-host protein-protein interactions: A complex hijacking of the cellular network. Open Virol J 6: 173-189.